Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.52
- Piotroski Score 2.00
- Grade Buy
- Symbol (TNYA)
- Company Tenaya Therapeutics, Inc.
- Price $2.08
- Changes Percentage (-0.48%)
- Change -$0.01
- Day Low $1.95
- Day High $2.09
- Year High $7.01
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/17/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.65
- Trailing P/E Ratio -2.21
- Forward P/E Ratio -2.21
- P/E Growth -2.21
- Net Income $-124,084,000
Income Statement
Quarterly
Annual
Latest News of TNYA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Tenaya Therapeutics, Inc. (TNYA) Stock Price, News, Quote & History - Yahoo Finance
Morgan Stanley predicts a potential 670% increase for two 'Strong Buy' stocks. The stock market has seen a 20% surge in the S&P 500 this year amidst the political uncertainty of the upcoming elections...
By Yahoo! Finance | 1 week ago -
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation
Despite losing money, shareholders can profit if they invest in a good business at the right price. Tenaya Therapeutics had a cash runway of 12 months in June 2024, with a cash burn of $99m annually....
By Yahoo! Finance | 1 week ago -
Owning 43% shares,institutional owners seem interested in Tenaya Therapeutics, Inc. (NASDAQ:TNYA),
Tenaya Therapeutics' stock price is influenced by institutional ownership, with institutions holding 43% of shares. This indicates credibility but also potential risks due to a crowded trade scenario....
By Yahoo! Finance | 1 month ago
